AU2007224438A1

AU2007224438A1 - Autoimmune conditions and NADPH oxidase defects

Info

Publication number: AU2007224438A1
Application number: AU2007224438A
Authority: AU
Inventors: Tomalchev Andrey Alekseevich; Anders Bergman; Marcel Linschoten; Peter Olofsson
Original assignee: Biovitrum AB
Current assignee: Swedish Orphan Biovitrum AB
Priority date: 2006-03-15
Filing date: 2007-03-15
Publication date: 2007-09-20
Anticipated expiration: 2027-03-15
Also published as: JP2010521412A; WO2007104790A1; CN101404985A; KR20090008233A; AU2007224438B2; NZ570803A; EP2004159A1; CA2643747A1

Description

WO 2007/104790 PCT/EP2007/052457 AUTOIMMUNE CONDITIONS AND NADPH OXIDASE DEFECTS TECHNICAL FIELD The present disclosure relates to methods and materials involved in treating, 5 preventing, and ameliorating one or more conditions associated with autoimmune conditions. In particular, the present disclosure relates to methods and materials involved in treating, preventing, or delaying the onset of arthritis and multiple sclerosis. BACKGROUND ART 10 Autoimmune conditions are conditions where a mammal's immune system reacts against its own tissues. Such conditions include, without limitation, arthritis (e.g., rheumatoid arthritis (RA)), multiple sclerosis (MS), inflammatory bowel disease, Crohn disease, lupus, autoimmune uveitis, type I diabetes, bronchial asthma, septic arthritis induced with staphylococci or streptococci, and cardiovascular disease 15 involving vasculitis. RA is a chronic inflammatory disease that can be found in about 1-2 % of the population. RA primarily affects peripheral joints where inflammatory synovitis leads to cartilage destruction, bone erosion, and ultimately to joint deformity and loss of joint function. RA is a complex disease in that both environmental factors as well as 20 multiple chromosomal regions are involved in susceptibility to RA. Inducers of arthritis in animal models include adjuvants, collagen (e.g., collagen type II) (collagen induced arthritis (CIA)), hexadecane (hexadecane induced arthritis (HIA)), oil (e.g., Freund's incomplete adjuvant), squalene (squalene induced arthritis (SIA), and pristane (pristane induced arthritis (PIA)). Chromosomal regions known to be associated with 25 development of RA include the major histocompatibility complex region. In addition, different genomic regions are known to control different phases of the disease such as onset, severity during the acute onset phase, and the severity of the destruction in the chronic relapsing phase. MS is a chronic inflammatory disease of the central nervous system. The 30 characteristic pathological feature is demyelination of the myelin sheath of neurons in the central nervous system, resulting in multiple and varied neurologic symptoms and signs, usually with repeated relapse and remission. MS affects more than 2 million people worldwide. Studies have implicated a cell-mediated immune response, involving T cells recognizing epitopes of myelin basic protein (MBP), in the pathogenesis of MS. 1 WO 2007/104790 PCT/EP2007/052457 Experimental autoimmune encephalomyelitis (EAE) is an autoimmune inflammatory and demyelinating disease model that shares many clinical and histological features with MS. EAE can be induced in susceptible strains of mice by immunization with self antigens derived from myelin. 5 The Ncfl gene, encoding the p47phox subunit of the NADPH oxidase complex, has been shown to be associated with the development of arthritis in the DA rat. (Olofsson et al. (2003) Nature Genetics 33:25-32; WO 03/095667), and the development of arthritis and encephalomyelitis in mice (Hultqvist et al. (2004) Proc Natl Acad Sci US A. 101:12646-51). 10 SUMMARY OF THE INVENTION Provided herein are methods and materials related to treating autoimmune conditions such as arthritis (e.g., RA), multiple sclerosis, lupus, autoimmune uveitis, 15 type I diabetes, bronchial asthma, septic arthritis induced with staphylococci or streptococci, and cardiovascular disease involving vasculitis. For example, this disclosure provides methods and materials involved in treating, preventing, ameliorating one or more symptoms associated with, and/or delaying the onset of autoimmune conditions. 20 The inventions described herein are based on the discovery that arthritis can be associated with or caused by a reduced level of NADPH oxidase activity. For example, development of severe arthritis symptoms in an arthritis animal model can be, at least partially, dependent upon the presence of low NADPH oxidase activity. In addition, the inventions are based on the discovery that mammals prone to develop arthritis can be 25 protected by providing those mammals with normal or increased levels of NADPH oxidase activity. The inventions are also based on the discovery that compounds that include one or more isoprenoid units (e.g., one or more unsaturated isoprenoid units and/or one or more saturated isoprenoid units) can be used as NADPH activators. NADPH activators 30 can be useful for treating, lessening the severity of the symptoms of, preventing, or delaying the onset of symptoms of an autoimmune condition in an animal such as a mammal. Typically, the compounds include at least one unsaturated isoprenoid unit or saturated isoprenoid unit that is derivatized with a functional moiety. A variety of 2 WO 2007/104790 PCT/EP2007/052457 compound classes useful as NADPH activators are described in more detail below (e.g., in compound classes 1-46). The invention features compounds; compositions (e.g., pharmaceutical compositions) containing the compounds described herein; and methods for treating a 5 mammal having an autoimmune condition (e.g., arthritis or multiple sclerosis) or ameliorating one or more symptoms of the autoimmune condition in such a mammal. In some embodiments, the compounds described herein for treating a mammal can be NADPH oxidase activators. In some embodiments, the compounds can include up to 10, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, one or more isoprenoid units (e.g., one or more 10 unsaturated isoprenoid units and/or one or more saturated isoprenoid units) conjugated to one another, in which the isoprenoid units can be arranged in any sequence or directionality (e.g., head to tail, head to head, tail to tail) relative to one another. One or more of the isoprenoid units (e.g., one or more unsaturated isoprenoid units and/or one or more saturated isoprenoid units) can be derivatized with one or more functional 15 moieties. The compounds can include derivatized isoprenoid units (e.g., derivatized unsaturated isoprenoid units and/or derivatized saturated isoprenoid units) arranged in any sequence or directionality relative to one another and in any sequence or directionality relative to underivatized isoprenoid units (e.g., unsaturated isoprenoid and/or underivatized saturated isoprenoid units). Particular compound classes are 20 described in more detail below. The compounds may be administered intra-dermally, intra-peritoneally, orally, or intra-nasally. In another embodiment, the invention features the use of one or more of the compounds described herein in the manufacture of a medicament to treat, prevent, delay 25 the onset of one or more symptoms, or ameliorate one or more symptoms of an autoimmune condition (e.g., arthritis or multiple sclerosis), wherein the composition enhances NADPH oxidase activity in a mammal. The compounds can have any of the structural formulae delineated herein including, e.g., the structural formulae associated with compound classes 1-46. 30 Another embodiment of the invention features a method of formulating a medicament for the treatment of an autoimmune condition, the method including: (a) contacting a sample comprising cells or a cellular fraction having NADPH activity with a test composition, (b) determining the level of NADPH oxidase activity in the sample, (c) determining whether or not the level is greater than a control level of NADPH 3 WO 2007/104790 PCT/EP2007/052457 oxidase activity, wherein the control level is the amount of NADPH oxidase activity in a control sample lacking the test composition, (d) identifying the test composition as a composition useful for treatment of the autoimmune condition when the level of NADPH oxidase activity is greater than the control level, and (e) formulating a 5 medicament from the composition for the treatment of the autoimmune condition. The autoimmune condition can be arthritis or multiple sclerosis. Test compounds can have any of the structural formulae delineated herein including, e.g., the structural formulae delineated in compound classes 1-46. In one aspect, this invention features a method for treating a mammal having an 10 autoimmune condition, the method includes administering to the mammal (e.g., a mammal in need thereof) a compound, or a pharmaceutically acceptable salt thereof, that enhances NADPH oxidase activity, wherein said compound includes one or more isoprenoid units. The autoimmune condition can be arthritis or multiple sclerosis. In another aspect, this invention features the compounds delineated herein (e.g., 15 genera, subgenera, or specific compounds set forth in compound classes 1-46). In a further aspect, this invention features a pharmaceutical composition, which includes one or more of the compounds delineated herein (e.g., genera, subgenera, or specific compounds set forth in compound classes 1-46) or a salt (e.g., a pharmaceutically acceptable salt) or a prodrug thereof and a pharmaceutically 20 acceptable adjuvant, carrier or diluent. In some embodiments, the composition can include an effective amount of the compound or the salt thereof. In some embodiments, the composition can further include an additional therapeutic agent. Embodiments can include one or more of the following features. The compound can include one or more unsaturated isoprenoid units. The 25 compound can include one or more saturated isoprenoid units. In embodiments, at least one of said unsaturated isoprenoid units or saturated isoprenoid units can be derivatized with a functional moiety. The compound can have the following general formula: 30 -m- -n in which: 4 WO 2007/104790 PCT/EP2007/052457 m + n = an integer from 0-9 (e.g., 0-5, 1-5, 2-5, 2-4, 2 or 3; e.g., one of m and n can be 0, and the other can be an integer from 1-9, e.g., 1-5, 1-4, 2-5, 2-4, 2 or 3; e.g., m + n = 0); - represents a single or double bond between C2 and C 3 ; and 5 Y can be a moiety, e.g., a functional moiety, that is present in the structural formulae associated with any of compound classes 1-46 (e.g., compound classes 1, 2, 13, 45, or 46). In embodiments, when variables R', R", and R'" are present, each of these variables can be independently of one another, H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which being optionally substituted 10 as described herein. In embodiments, Y can be -OR' or -O-C(=O)R', in which R' can be H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted (e.g., Y can be hydrogen; optionally substituted alkyl, optionally substituted aryl; or heteroaryl). 15 In embodiments, Y can be OR'. R' can be hydrogen. In embodiments, Y can be -O-C(=O)R'. R' can be C 1

-C

6 alkyl (e.g., CH 3 ). One of m and n can be 0. The other of m and n can be an integer from 1-9, e.g., 1-5, 1-4, 2-5, 2-4, 2 or 3 (e.g., 2-4). For example, n can be 0, and m can be an integer from 1-9, e.g., 1-5, 1-4, 2-5, 2-4, 2 or 3. As another example, m can be 0, and n can be 20 an integer from 1-9, e.g., 1-5, 1-4, 2-5, 2-4, 2 or 3. In embodiments, m + n = 3. One of m and n can be 0 (e.g., n can be 0, and m can be 3 or vice versa). In embodiments, m + n = 2. One of m and n can be 0 (e.g., n can be 0, and m can be 2 or vice versa). 25 In embodiments, - can represent a double bond between C 2 and C3; or a single bond between C 2 and C 3 . The compound can be selected from the group consisting of: 5 WO 2007/104790 PCT/EP2007/052457 (3,7,11,15-Tetramethyl-2-hexadecen- 1 -ol); Farnesol (3,7,11-Trimethyl-2,6,10-dodecatrien- 1-ol); Geranylgeraniol (3,7,11,15-Tetramethyl-hexada- 2,6,10,14-tetraen- 1-ol); Farnesyl acetate (Acetic acid 3,7,11-trimethyl-dodeca-2,6,10-trienyl ester); 5 Phytyl acetate (Acetic acid 3,7,11,15-tetra-metyl-hexadec-2-enyl-ester); Di-hydro-phytol (3,7,11,15-Tetramethyl-hexadecan-l1-ol); and Di-hydro-phytyl acetate (Acetic acid 3,7,11,15-tetramethyl-hexadecyl ester); In certain embodiments, the compound can be (3,7,11,15-Tetramethyl-2 hexadecen-1-ol). The compound can have the general formula: 15 i OR' 20 m + n = an integer from 0-9 (e.g., 0-5, 1-5, 2-5, 2-4, 2 or 3; e.g., one of m and n can be 0, and the other can be an integer from 1-9, e.g., 1-5, 1-4, 2-5, 2-4, 2 or 3; e.g., m + n = 0); R' can be H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted (e.g., R' can be hydrogen; optionally substituted 25 alkyl, optionally substituted aryl; or heteroaryl). In certain embodiments, R' can be hydrogen. In embodiments, one of m and n can be 0. The other of m and n can be an integer from 1-9, e.g., 1-5, 1-4, 2-5, 2-4, 2 or 3 (e.g., 2-4). For example, n can be 0, and m can be an integer from 1-9, e.g., 1-5, 1-4, 2-5, 2-4, 2 or 3. As another example, m can 30 be 0, and n can be an integer from 1-9, e.g., 1-5, 1-4, 2-5, 2-4, 2 or 3. In embodiments, m + n = 3. One of m and n can be 0 (e.g., n can be 0, and m can be 3 or vice versa). In embodiments, m + n = 2. One of m and n can be 0 (e.g., n can be 0, and m can be 2 or vice versa). 35 The compound can be 3,7,11,15-tetramethyl- 1 -hexadecen-3-ol. The compound has the general formula: 40 m 6- n WO 2007/104790 PCT/EP2007/052457 m + n = an integer from 0-9 (e.g., 0-5, 1-5, 2-5, 2-4, 2 or 3; e.g., one of m and n 5 can be 0, and the other can be an integer from 1-9, e.g., 1-5, 1-4, 2-5, 2-4, 2 or 3; e.g., m + n = 0); R' can be H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted (e.g., R' can be hydrogen; optionally substituted alkyl, optionally substituted aryl; or heteroaryl, e.g., R' can be hydrogen or optionally 10 substituted alkyl). In certain embodiments, R' can be optionally substituted alkyl. In embodiments, one of m and n can be 0. The other of m and n can be an integer from 1-9, e.g., 1-5, 1-4, 2-5, 2-4, 2 or 3. For example, n can be 0, and m can be an integer from 1-9, e.g., 1-5, 1-4, 2-5, 2-4, 2 or 3. As another example, m can be 0, and n can be an integer from 1-9, e.g., 1-5, 1-4, 2-5, 2-4, 2 or 3. 15 In embodiments, m + n = 3. One of m and n can be 0 (e.g., n can be 0, and m can be 3 or vice versa). In embodiments, m + n = 2. One of m and n can be 0 (e.g., n can be 0, and m can be 2 or vice versa). R' can be C 1

-C

3 alkyl substituted with from 1-3 (e.g., 2) halogens, (e.g., fluoro 20 (F). The compound can be 6-Difluoromethoxy-2,5,7,8-tetramethyl-2-(4,8,12 trimethyl-tridecyl)-chroman. The compound can be administered intra-dermally, intra-peritoneally, orally, or intra-nasally. 25 Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, 30 patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting. 7 WO 2007/104790 PCT/EP2007/052457 Other features and advantages of the invention will be apparent from the following detailed description, and from the claims. DESCRIPTION OF DRAWINGS 5 Figures 1A-E set forth synthetic reaction schemes for using and preparing the compound classes described herein. The bolded number underneath a compound corresponds to the particular compound class, while R, R', R", and R"' convey one or more isoprenoid units and/or one or more saturated isoprenoid units conjugated to one another. 10 Figure 2 is a graph illustrating oxidative burst of granulocytes after in vitro stimulation with compound 1 (phytol) (*),compound 2 (farnesol) (0), compound 3 (geranyl geraniol) (A) or pristane (0). Figure 3 is a bar graph demonstrating oxidative burst response to PMA stimulation in vitro in spleen granulocytes taken 5 days after s.c. injection of 15 compound 1 (phytol) in DA.Ncfl D A rats (200 pl) (Ph), compared to naive DA.Ncfl D A and DA.NcflE 3 (n=5). Figure 4 is a set of bar graphs illustrating the tissue distribution of 3H-labeled compound 1 (phytol) at day 2, 4, 8, 11, and 17 post-injection. Figure 5 is a graph demonstrating the severity of PIA in DA.Ncfl D A rats treated 20 with injection of compound 1 (phytol) (A) compared with untreated DA.Ncfl D A rats (A).*P<0.05, **P<0.01, ***P<0.001. Figure 6 is a set of graphs illustrating the effect of treatment of established PIA with compound 1 (phytol). Figure 6A demonstrates the severity of arthritis in DA.Ncfl D A rats after injections of compound 1 at the estimated peak of disease (day 25 22). (Significance indications above line represent s.c. administration and below i.p. administration) (control (A), compound 1 (phytol) i.p (0), compound 1 (phytol) s.c. (A)). *P<0.05, **P<0.01, ***P<0.001. Figure 6B shows the effect of injections of compound 1 on serum levels of COMP (ng/ml). Figure 6C demonstrates the severity of arthritis in DA.Ncfl D A rats after injections of compound 1 in the chronic phase, (control 30 (A) and compound 1 (phytol) s.c. (A)), *P<0.05, **P<0.01, ***P<0.001. Figure 6D demonstrates the effect of injections of compound 1 on the severity of arthritis in Lewis.IF rats (control (A) and compound 1 (phytol) s.c. (A)), *P<0.05, **P<0.01, ***P<0.001. Figure 6E demonstrates the effect injections of compound 1 on the 8 WO 2007/104790 PCT/EP2007/052457 severity of arthritis in rats with a functional oxidative burst (control (A) and compound 1 (phytol) (A)), *P<0.05, **P<0.01, ***P<0.001. Figure 7 is a set of graphs illustrating the effect of compound 1 (phytol) on collagen induced arthritis in DA.Ncfl DA rats. Figure 7A demonstrates the severity of 5 arthritis after s.c. administration of compound 1 (phytol) before immunization with CII (control (A) n=7, compound 1 (phytol) (A) n=8). Figure 7B shows the level of CII antibodies in serum. Figure 8 is a set of graphs illustrating the effect of compound 1 (phytol) on non oil collagen induced arthritis in DA.Ncfl DA rats. Figure 8A demonstrates the severity of 10 arthritis after s.c. administration of compound 1 (phytol) before immunization with CII (n=7), (control (A) and compound 1 (phytol) (A)). Figure 8B shows the effect on the level of DTH response of phytol injection as measured by increase in ear volume (control n=7 and compound 1 (phytol) n=8). *P<0.05, **P<0.01, ***P<0.001I Figure 9 is a graph demonstrating the severity of PIA in DA.Ncfl DA rats treated 15 with injections of compound 1 (phytol) (*) or compound 5 (phytyl acetate) (A). Untreated control (0). Figure 10 is a graph demonstrating the severity of PIA in DA.NcflDA rats treated with injections of compound 1 (phytol) (*) or compound 8 (A). Untreated control (0). Figure 11 is a graph demonstrating the severity of PIA in DA.Ncfl DA rats treated 20 with injections of compound 2 (farnesol) (0) or compound 4 (farnesyl acetate) (A). Untreated control (0). Figure 12 is a graph demonstrating the severity of PIA in DA.NcflDA rats treated with injections of compound 1 (phytol) (*), compound 6 (di-hydro-phytol (U), compound 5 (phytyl acetate) (A) or compound 7 (di-hydro-phytyl acetate 25 (*).Untreated control (0). Figure 13 is a graph demonstrating the severity of PIA in DA.NcflDA rats treated with oral administration of phytol 1% daily (7202244831), phytol 1% every 2'nd day (A), or phytol 1% initiated day 7 after arthritis induction. Untreated control (0), Omega3 fatty acid (0I). 30 Figure 14 is a graph demonstrating the severity of PIA in DA.Ncfl DA rats treated with oral administration of compound 1 (phytol) 1% daily (*) or compound 5 (phytyl acetate) 1% daily (A). Untreated control (0). 9 WO 2007/104790 PCT/EP2007/052457 Figure 15 is a graph illustrating oxidative burst of granulocytes after in vitro stimulation with compound 1 (phytol) (*), compound 2 (farnesol) (A) or compound 9 (isophytol) (0). Figure 16 is a graph demonstrating the severity of PIA in DA.Ncfl D A rats treated 5 by oral gavage with compound 1 (phytol) 1.6 g/kg/every second day (*), compound 1 (phytol) 3.2 g/kg/every second day (A) or untreated control (0). Figure 17 is a graph demonstrating the severity of PIA in DA.Ncfl D A rats treated with oral administration of compound 1 (phytol) 500 mg/kg/day (*), compound 9 (isophytol) 500 mg/kg/day (A), or fenofibrate 100mg/kg/day (0) or untreated control 10 (0). Figure 18 is a graph demonstrating the effect of compound 1 (phytol) on the development of EAE in DA.Ncfl D A rats treated with parenteral administration of compound 1 (phytol) (*) or untreated control (0). 15 DETAILED DESCRIPTION The invention provides methods and materials related to treating autoimmune conditions (e.g., arthritis and multiple sclerosis). In particular, compounds that include one or more one or more isoprenoid units (e.g., one or more unsaturated isoprenoid units and/or one or more saturated isoprenoid units); compositions, e.g., pharmaceutical 20 compositions, containing such compounds; and methods for using the same to treat or to alleviate the symptoms of autoimmune disease are described. 1. Compositions of Matter The invention provides compounds useful for treating autoimmune diseases. In embodiments, the compounds can enhance NADPH oxidase activity. Pharmaceutically 25 acceptable derivatives of any of the compounds described herein, e.g. compounds having any of the structural formulae delineated in compound classes 1-46,are also contemplated. Pharmaceutical compositions including any of the compounds described herein, e.g., in combination with a pharmaceutically acceptable carrier or diluent, are also contemplated. 30 As used herein, "pharmaceutically acceptable derivatives" of a compound include salts, esters, enol ethers, enol esters, acetals, ketals, orthoesters, hemiacetals, hemiketals, acids, bases, solvates, hydrates or prodrugs thereof. Such derivatives may be readily prepared by those of skill in this art using known methods for such 10 WO 2007/104790 PCT/EP2007/052457 derivatization. The compounds produced may be administered to animals or humans without substantial toxic effects and either are pharmaceutically active or are prodrugs. Pharmaceutically acceptable salts include, but are not limited to, amine salts, such as but not limited to N,N'-dibenzylethylenediamine, chloroprocaine, choline, 5 ammonia, diethanolamine and other hydroxyalkylamines, ethylenediamine, N methylglucamine, procaine, N-benzylphenethylamine, 1-para-chlorobenzyl-2 pyrrolidin-l1'-ylmethyl-benzimidazole, diethylamine and other alkylamines, piperazine and tris(hydroxymethyl)aminomethane; alkali metal salts, such as but not limited to lithium, potassium and sodium; alkali earth metal salts, such as but not limited to 10 barium, calcium and magnesium; transition metal salts, such as but not limited to zinc; and other metal salts, such as but not limited to sodium hydrogen phosphate and disodium phosphate; and also including, but not limited to, nitrates, borates, methanesulfonates, benzenesulfonates, toluenesulfonates, salts of mineral acids, such as but not limited to hydrochlorides, hydrobromides, hydroiodides and sulfates; and salts 15 of organic acids, such as but not limited to acetates, trifluoroacetates, maleates, oxalates, lactates, malates, tartrates, citrates, benzoates, salicylates, ascorbates, succinates, butyrates, valerates and fumarates. Pharmaceutically acceptable esters include, but are not limited to, alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, heteroaralkyl, cycloalkyl and heterocyclyl esters of acidic groups, including, but not limited to, carboxylic acids, 20 phosphoric acids, phosphinic acids, sulfonic acids, sulfinic acids and boronic acids. Pharmaceutically acceptable enol ethers include, but are not limited to, derivatives of formula C=C(OR) where R is hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, heteroaralkyl, cycloalkyl or heterocyclyl. Pharmaceutically acceptable enol esters include, but are not limited to, derivatives of formula C=C(OC(O)R) where R is 25 hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, heteroaralkyl, cycloalkyl or heterocyclyl. Pharmaceutically acceptable solvates and hydrates are complexes of a compound with one or more solvent or water molecules, or 1 to about 100, or 1 to about 10, or one to about 2, 3 or 4, solvent or water molecules. As used herein, treatment means any manner in which one or more of the 30 symptoms of an autoimmune condition, such as arthritis or multiple sclerosis, are ameliorated or otherwise beneficially altered. Treatment also encompasses any pharmaceutical use of the compounds or compositions herein, such as uses for treating diseases, disorders, or ailments in which an autoimmune condition is suspected or implicated, e.g., in a mammal such as a human. 11 WO 2007/104790 PCT/EP2007/052457 As used herein, amelioration of the symptoms of a particular disorder by administration of a particular compound or pharmaceutical composition refers to any lessening, whether permanent or temporary, lasting or transient that can be attributed to or associated with administration of the composition. 5 Typically, a compound includes one or more isoprenoid units, and more specifically one or more unsaturated isoprenoid units and/or one or more saturated isoprenoid units. As used herein, the term "isoprenoid unit" refers to a five carbon unit that is represented by the structure: 10 20 where represents a single or a double bond. The term "unsaturated isoprenoid unit" refers to a five carbon unit that is 25 represented by the structure: m* The term "saturated isoprenoid unit" refers to a five carbon unit that is represented by the structure: 30 12 WO 2007/104790 PCT/EP2007/052457 For purposes of clarification, the right most line (i.e., the line that extends rightward from the "head" of the isoprenoid unit and having the terminus labelled with the asterisk (*)) in each of the above three structural representations (as well as other such representations shown throughout the specification and claims) is intended to 5 represent a covalent bond that can occur (i) between the "head" terminus of said isoprenoid unit and, e.g., a tail or head terminus of another unsaturated or saturated isoprenoid unit; or (ii) between the "head" terminus of said isoprenoid unit and an atom that forms part of another structural moiety, e.g. a functional moiety (i.e., the terminus marked with the asterisk (*) in the aforementioned structures is not intended to show a 10 sixth carbon atom attached to the head of said isoprenoid unit). By way of example, a compound that contains a saturated isoprenoid unit that is directly connected, in head to tail fashion, to an unsaturated isoprenoid unit would have the following structure: 15 20 The bolded line in the above 10-carbon structure represents the covalent bond between the head terminus of the saturated isoprenoid unit and the tail terminus of the unsaturated isoprenoid unit. In some embodiments, the unsaturated isoprenoid and/or saturated isoprenoid units can be conjugated (e.g., covalently bound) to one another. Thus, as used herein, 25 brackets around an unsaturated isoprenoid and/or saturated isoprenoid unit structure represent the ability of a unit to be conjugated at either the head or tail termini, e.g., to another unit. In certain embodiments, a compound can include up to 10 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, e.g., 2, 3, or 4, e.g., 2 or 3, e.g. 3) unsaturated isoprenoid units and/or saturated isoprenoid units conjugated to one another. A compound can include 30 unsaturated isoprenoid units and/or saturated isoprenoid units arranged in any sequence or directionality relative to one another. In some embodiments, one or more of the unsaturated isoprenoid units and/or saturated isoprenoid units can be derivatized with one or more functional moieties. A compound can include derivatized unsaturated isoprenoid units and/or derivatized 35 saturated isoprenoid units arranged in any sequence or directionality relative to one another and in any sequence or directionality relative to underivatized unsaturated isoprenoid units and/or underivatized saturated isoprenoid units. Thus, a derivatized 13 WO 2007/104790 PCT/EP2007/052457 unsaturated isoprenoid unit or a derivatized saturated isoprenoid unit can be at any position in a compound, e.g., at an internal or at a terminal unit. For example, a compound can include a saturated isoprenoid unit conjugated to an unsaturated isoprenoid unit, which is in turn conjugated to a derivatized (saturated or unsaturated) 5 isoprenoid unit. In another example, a compound can include three saturated isoprenoid units, with the second saturated isoprenoid unit conjugated to the third derivatized saturated isoprenoid unit. In some embodiments, a functional moiety can be conjugated (e.g., covalently bound) to an unsaturated isoprenoid unit and/or saturated isoprenoid unit at any carbon 10 position in the unit, e.g., at a terminal, branching, or internal carbon atom of the unit. A functional moiety can comprise any functional group, including, without limitation, alkyl, alkenyl, alkynyl, cycloalkyl, alcohol, ketone, aldehyde, carboxylic acid, carboxylic acid ester, thio ester, carbamate, halide, alkyl ether, aryl ether, thio ether, amine, amide, heterocyclic (e.g., piperazinyl), heteroaryl (thienyl, furyl, pyridyl) or aryl 15 (e.g., phenyl or naphthyl) groups, or combinations thereof. The term "alkyl" refers to a saturated hydrocarbon chain that may be a straight chain or branched chain, containing the indicated number of carbon atoms. For example, the term "C 1 -20-alkyl" denotes a straight or branched alkyl group having from 1 to 20 carbon atoms. Examples of alkyl include methyl, ethyl, n-propyl, iso-propyl, n 20 butyl, iso-butyl, sec-butyl, t-butyl and straight- and branched-chain pentyl and hexyl. For parts of the range "C 1 -20-alkyl" all subgroups thereof are contemplated (e.g., C 1

-C

1 2 ,

C

1 -Co 10 , C 1

-C

6 , or C 1

-C

3 linear or branched saturated chains). The term "alkenyl" refers to a straight or branched hydrocarbon chain containing 2-20 carbon atoms and having one or more double bonds. The term "alkynyl" refers to 25 a straight or branched hydrocarbon chain containing 2-20 carbon atoms and having one or more triple bonds. Examples of said alkenyl include vinyl, allyl, 1-butenyl, 1 pentenyl, and 1-hexenyl. Examples of alkynyl include ethynyl, propargyl, and 3 hexynyl. For parts of the ranges "C 2 -20-alkenyl" and "C 2 -20-alkynyl," all subgroups thereof are contemplated (e.g., C 2

-C

1 2 , C 2 -Co 1 0 , C 2

-C

6 , or C 2

-C

4 linear or branched). 30 The term "cycloalkyl" refers to saturated monocyclic, bicyclic, tricyclic, or other polycyclic hydrocarbon C 3

-C

20 (e.g., C 3 -Co 10 , C 3 -Cs, C 3

-C

6 ) rings. Cycloalkyl groups can contain fused rings. Fused rings are rings that share a common carbon atom. Cycloalkyl moieties can include, e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl, and norbornyl (bicycle[2.2.1]heptyl). 14 WO 2007/104790 PCT/EP2007/052457 Alkyl, alkenyl, alkynyl, and cycloalkyl groups can be optionally substituted (e.g., with from 1-5 (e.g., 1-4, 1-3, 1-2, or 1) substituents, e.g., X (e.g., F, Cl, Br, I),

NH

2 , NO 2 , CN, OH, alkyl, cycloalkyl, or carboxylic acid ester moieties (or any combination thereof). 5 The term "aryl" refers to a hydrocarbon ring System having at least one aromatic ring. Examples of aryls are phenyl, pentalenyl, indenyl, indanyl, isoindolinyl, chromanyl, naphthyl, fluorenyl, anthryl, phenanthryl and pyrenyl. Aryl groups may be substituted optionally with one or more (e.g., with from 1-5 (e.g., 1-4, 1-3, 1-2, or 1) substituents such as X (e.g., F, Cl, Br, I), NH 2 , NO 2 , CN, OH, alkyl (e.g.,CH 3 ), or 10 carboxylic acid ester moieties (or any combination thereof when more than one substituent is present). The term "heteroaryl" means in the present description a monocyclic, bi- or tricyclic aromatic ring System (only one ring need to be aromatic) having from 5 to 14, preferably 5 to 10 ring atoms such as 5, 6, 7, 8, 9 or 10 ring atoms (mono- or bicyclic), 15 in which one or more of the ring atoms are other than carbon, such as nitrogen, sulfur, oxygen and selenium as part of the ring System. Examples of such heteroaryl rings are pyrrole, imidazole, thiophene, furan, thiazole, isothiazole, thiadiazole, oxazole, isoxazole, oxadiazole, pyridine, pyrazine, pyrimidine, pyridazine, pyrazole, triazole, tetrazole, chroman, isochroman, quinoline, quinoxaline, isoquinoline, phthalazine, 20 cinnoline, quinazoline, indole, isoindole, indoline (i e 2,3-dihydroindole), isoindoline (i e 1,3-dihydroisoindole), benzothiophene, benzofuran, 2,3-dihydrobenzofuran, isobenzofuran, benzodioxole, benzothiadiazole, benzotriazole, benzoxazole, 2,1,3 benzoxadiazole, benzopyrazole, 2,1,3-benzothiazole, 2,1,3-benzoselenadiazole, benzimidazole, indazole, benzodioxane, 2,3-dihydro-1,4-benzodioxine, indane, 1,2,3,4 25 tetrahydroquinoline, 3,4-dihydro-2H-1,4-benzoxazine, 1,5-naphthyridine, 1,8 naphthyridine, pyrido[3,2-b]thiophene, acridine, fenazine and xanthene. Heteroaryl groups may be substituted optionally with one or more(e.g., with from 1-5 (e.g., 1-4, 1 3, 1-2, or 1) substituents such as X (e.g., F, Cl, Br, I), NH 2 , NO 2 , CN, OH, CH 3 , or carboxylic acid ester moieties (or any combination thereof when more than one 30 substituent is present). The term "heterocyclic" and "heterocyclyl" in the present description is intended to include unsaturated as well as partially and fully saturated mono-, bi- and tricyclic rings having from 4 to 14, preferably 4 to 10 ring atoms having one or more heteroatoms (e.g., oxygen, sulfur, or nitrogen) as part of the ring System and the 15 WO 2007/104790 PCT/EP2007/052457 reminder being carbon, such as, for example, the heteroaryl groups mentioned above as well as the corresponding partially saturated or fully saturated heterocyclic rings. Exemplary saturated heterocyclic rings are azetidine, pyrrolidine, piperidine, piperazine, morpholine, thiomorpholine, 1,4-oxazepane, azepane, phthalimide, indoline, 5 isoindoline, 1,2,3,4-tetrahydroquinoline, 1,2,3,4-tetrahydroisoquinoline, hexahydroazepine, 3,4-dihydro-2(1H)isoquinoline, 2,3-dihydro- 1H-indole, 1,3-dihydro 2H-isoindole, azocane, 1-oxa-4-azaspiro[4.5]dec-4-ene, decahydroisoquinoline, 1,2 dihydroquinoline, and 1,4-diazepane. Heterocyclic groups groups may be substituted optionally with one or more(e.g., with from 1-5 (e.g., 1-4, 1-3, 1-2, or 1) substituents 10 such as X (e.g., F, Cl, Br, I), NH 2 , NO 2 , CN, OH, CH 3 , or carboxylic acid ester moieties (or any combination thereof when more than one substituent is present). Generic formulae for particular classes of compounds are described below. Representative species for each generic formula are also set forth. 15 Compound class 1 includes branched alcohols having the general formula: [ *lm " *ln OH -m- -n where n+m is an integer from 0 to 9. Particular species include: OH 20 3-Methyl-but-2-en- 1-ol (3,3-Dimethyl-allyl alcohol, Prenol); OH. 3,7-Dimethyl-octa-2,6-dien- 1-ol 25 (Geraniol); OH 3,7-Dimethyl-oct-2-en- 1-ol; 16 WO 2007/104790 PCT/EP2007/052457 OH 3,7,11 ,-Trimethyl-dodeca-2,6,10-trien- 1-ol (Farnesol); 5 OH 3,7,1 1,-Trimethyl-dodec-2-en- 1-ol; OH 10 3,7,11,15-Tetramethyl-hexadec-2-en- 1-ol (Phytol); OH 3,7,11,15-Tetramethyl-hexadeca-2,6,10,14-tetraen- 1-ol 15 (Geranylgeraniol); OH 3,7,11,15-Tetramethyl-hexadeca-2,6-dien- 1-ol; 20 OH 3,7,11,15,19-Pentamethyl-icosa-2,6,10,14,18-pentaen-1-ol (Geranylfarnesol); OH 25 3,7,11,15,19-Pentamethyl-icos-2-en- 1-ol; 17 WO 2007/104790 PCT/EP2007/052457 OH 3,7,11,15,19,23-Hexamethyl-tetracosa-2,6,10,14,18,22-hexaen- 1 -ol (Farnesylfarnesol); 5 3,7,11,15,19,23,27,31,35-Nonaamethyl-hexatriaconta-2,6,10,14,18,22,26,30,34 nonaen- 1-ol 10 (Solanesol); and OH 3,7-Dimethyl-oct-6-en- 1-ol; (Citronellol). 15 Compound class 2 includes carboxylic acid esters having the general formula: * * O"" R' where n+m is an integer from 0 to 9; and where R' can be, e.g., H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is 20 optionally substituted. Particular compounds include: 0 3-Methyl-butyric acid 3,7-dimethyl-octa-2,6-dienyl ester (Geranyl butyrate); 25 18 WO 2007/104790 PCT/EP2007/052457 0 Acetic acid 3,7,11-trimethyl-dodeca-2,6,10-trienyl ester (Farnesyl acetate); 0 5 O Propionic acid 3,7,11,15-tetramethyl-hexadec-2-enyl ester (Phytyl propionate); 0 10 Hexadecanoic acid 3,7,11,15-tetramethyl-hexadec-2-enyl ester (Phytyl palmitate); 0 15 Octadecanoic acid 3,7,11,15-tetramethyl-hexadec-2-enyl ester (Phytyl stearate); 0 20 20 Octadec-9-enoic acid 3,7,11,15-tetramethyl-hexadec-2-enyl ester (Phytyl oleate); O 25 Octadeca-9,12-dienoic acid 3,7,11,15-tetramethyl-hexadec-2-enyl ester (Phytyl linoleate); 19 WO 2007/104790 PCT/EP2007/052457 0 Octadeca-9,12,15-trienoic acid 3,7,11,15-tetramethyl-hexadec-2-enyl ester (Phytyl linolenate); 5 O Eicosa-5,8,11,14-tetraenoic acid 3,7,11,15-tetramethyl-hexadec-2-enyl ester (Phytyl aracidonate); 10 0 0 °.¢ O 0 Succinic acid di-(3,7,11,15-tetramethyl-hexadec-2-enyl) ester (Di-phytyl succinate); 15 0 ....... .-. . ............. 0 O 0 Succinic acid -(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-(3,7-dimethyl-octa-2,6 dienyl) ester (Farnesyl-geranyl-succinate); 20 20 WO 2007/104790 PCT/EP2007/052457 0 0 0 HO 0, 0 Citric acid tri-(3,7,11-trimethyl-dodeca-2,6,19-trienyl) ester (Tri-famesyl citrate); 00 5O Benzoic acid 3,7-dimethyl-octa-2,6-dienyl ester (Geranyl bensoate); O OH 10 2-Hydroxy-benzoic acid 3,7,11,15-tetramethyl-hexadec-2-enyl ester (Phytyl salicylate); 00 0 /N 4-Amino-benzoic acid 3,7,1 1,-trimethyl-dodec-2-enyl ester; 15 0 Cyclopenta-1,3-dienecarboxylic acid 3,7,11,15-tetramethyl-hexadec-2-enyl ester (Phytyl cyclopenta- 1,3-dienecarboxylate); 21 WO 2007/104790 PCT/EP2007/052457 0 Nicotinic acid 3,7,11,15-tetramethyl-hexadec-2-enyl ester (Phytyl nicotinate); 0 5 Furan-2-carboxylic acid 3,7,11,15-tetramethyl-hexadec-2-enyl ester (Phytyl-2-furoate); and 0 O 10 Thiophen-2-carboxylic acid 3,7,11,15-tetramethyl-hexadeca-2,6,10,14-tetraenyl ester. 15 Compound class 3 includes carbamates with the general formula: * * O N R' -m- -n where n+m can be an integer from 0 to 9; and where R' is, e.g., H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted. Particular examples include: 0 20 O N Cyclohexyl-carbamic acid 3,7-dimethyl-oct-2-enyl ester; 22 WO 2007/104790 PCT/EP2007/052457 Ethyl carbamic acid 3,7,11,15-tetramethyl-hexadec-2-enyl ester (Phytyl N-ethyl carbamate); O 5 ON Phenyl carbamic acid 3,7,11,15-tetramethyl-hexadec-2-enyl ester (Phytyl N-phenyl carbamate); ON 0 N OH 10 (2-Hydroxy-phenyl)-carbamic acid 3,7,11 -trimethyl-dodeca-2,6,10-trienyl ester (Farnesyl N-2-hydroxy-phenyl carbamate); ON N Pyridin-4-yl carbamic acid 3,7,11,15-tetramethyl-hexadec-2-enyl ester 15 (Phytyl N-pyridin-4-yl carbamate); Furan-2-yl carbamic acid 3,7,11,15-tetramethyl-hexadec-2-enyl ester (Phytyl N-furan-2-yl carbamate); 20 and 23 WO 2007/104790 PCT/EP2007/052457 Thiophen-2-yl carbamic acid 3,7,11,15,19-pentamethyl-icosa-2,6,10,14,18 pentaenyl ester. 5 Compound class 4 substitutes a halogen moiety for the hydroxy moiety in composition class 1. Halogen moieties include F, Cl, Br, and I. Compound class 5 includes aryl ethers with the general formula: *lm[* N O Ar -m- -n o10 where n+m is an integer from 0 to 9; and Ar is optionally substituted aryl (e.g., phenyl). These compounds are exemplified by: O 1,3,5 Trimethyl-2-(3,7,11-trimethyl-dodeca-2,6,10-trienyloxy)-benzene; 15 and (3,7,11,15-Tetramethyl-hexadec-2-enyloxy)-benzene. 20 24 WO 2007/104790 PCT/EP2007/052457 Compound class 6 includes thio ethers with the general formula: *lm *1 SR -m -n where n+m is an integer from 0 to 9; and where R' is, e.g., H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is optionally 5 substituted. Particular examples include: 1 -Ethylsulfanyl-3,7,11,15-tetramethyl-hexadec-2-en; 10 1-(3,7,11-Trimethyl-dodeca-2,6,10-triensulfanyl)-hexadecane; 15 (3,7,11,15-Tetramethyl-hexadec-2-enylsulfanyl)-benzene;S 15 (3,7,11,15-Tetramethyl-hexadec-2-enylsulfanyl)-benzcyclopene;ta- 1,3-diene; 5-(3,7,11,15-Tetramethyl-hexadec-2-enylsulfanyl)-cyclopenta- 1,3-diene; 20 S 4-(3,7,11,15-Tetramethyl-hexadeca-2,6,10,14-tetraenylsulfanyl)-pyridine; 25 WO 2007/104790 PCT/EP2007/052457 S 2-(3,7,11,15-Tetramethyl-hexadec-2-enylsulfanyl)-furan; and 5 S 2-(3,7,11,15-Tetramethyl-hexadec-2-enylsulfanyl)-thiophen. 10 Compound class 7 include amines with the general formula: [ *lm[N, R' m - nI R" where n+m= an integer from 0 to 9; and where R' and R" independently are, e.g., H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted. Examples include: 15 N Diethyl-(3,7,11,15-Tetramethyl-hexadec-2-enyl)-amine; N 20 Ethyl-hexadecyl-(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-amine; (3,7-Dimethyl-octa-2,6-dienyl)-dihexadecyl-amine; 26 WO 2007/104790 PCT/EP2007/052457 Ethyl-phenyl-(3,7,11,15-tetramethyl-hexadec-2-enyl)-amine; 5 and N (3,7,11,15-Tetramethyl-hexadec-2-enyl)-di-thiophen-2-yl-amine. 10 Compound class 8 includes compounds with the general formula: m -n R' where (n+m) and (p+q) independently are an integer from 0 to 9; and R' and R" independently are, e.g., H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or 15 heteroaryl, each of which is optionally substituted. Examples include: 17,17,diethyl-2,6,10,14,20,24,28,32-octamethyl-tritriaconta-14,19-diene; 27 WO 2007/104790 PCT/EP2007/052457 [2-Ethyl-5,9,13,17-tetramethyl-2-(3,7,11,15-tetramethyl-hexadec-2-enyl) octadec-4-enyl]-benzene; 5 13,13-Diethyl-2,6,10,16,20-pentamethyl-henicosa-2,6,10,15,19 pentaene; and o10 2,6,10,13,13,16,20,24- Octamethyl-pentacosa-2,6,10,15,19,23-hexaene. Compound class 9 includes compounds having the general formula: m n /-R" 15 where n+m=an integer from 0 to 9; and R', R" and R"' independently aree.g., H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted. Examples include: 3,3-Diethyl-6,10,14,18-tetramethyl-nonadec-5-ene; 20 28 WO 2007/104790 PCT/EP2007/052457 and (2,2-Diethyl-,5,9,13,17-tetramethyl-octadeca-4,8,12,16-tetraenyl)-benzene. 5 Compound class 10 includes carboxylic acids with the general formula: *m OH -m- -n where n+m= an integer from 0 to 13, exemplified by: 10 OH 3,7,11,15-Tetramethyl-hexadec-2-enoic acid; OH 15 3,7,11-Trimethyl-dodeca-2,6,10-trienoic acid; and 0 OH 3,7-Dimethyl-octa-2,6-dienoic acid 20 (Geranic acid). 29 WO 2007/104790 PCT/EP2007/052457 Compound class 11 includes amides of the general formula: 0 * * NR' -m n \R" where n+m=an integer from 0 to 9; and R' and R" independently are, e.g., H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is 5 optionally substituted. Examples include: 0 N 3,7,11,15-Tetramethyl-hexadec-2-enoic acid diethylamide; 10 3,7,11-Trimethyl-dodeca-2,6,10-trienoic acid hexadecylamide; and N 15 3,7,11,15-Tetramethyl-hexadec-2-enoic acid phenylamide. Compound class 12 includes carboxylic acid esters with the general formula: * m* O, -m- -n 20 where n+m=an integer from 0 to 9; and R' is alkyl, aryl, or heteroaryl. Examples include: 30 WO 2007/104790 PCT/EP2007/052457 o 3,7,11,15-Tetramethyl-hexadec-2-enoic acid ethyl ester (Phytanic acid ethyl ester); 0 5 0 3,7,11,15-Tetramethyl-hexadec-2-enoic acid octadecen-9-yl ester; 0 10 3,7,11,15-Tetramethyl-hexadec-2-enoic acid phenyl ester; 0 oN 3,7,11,15,19-Pentamethyl-icosa-2,6,10,14,18-pentaenoic acid pyridin-4-yl ester; 0 0 0 15 3,7,11-Trimethyl-dodeca-2,6,10-trenoic acid 4-(3,7,11-trimethyl-dodeca-2,6,10 trenoyloxy)-butyl ester; 0 0 20 3,7,11,15-Tetramethyl-hexadeca-2-enoic acid 4-(3,7-dimethyl-oct-6-enoyloxy) butyl ester; and 31 WO 2007/104790 PCT/EP2007/052457 O 3,7,11,15-Tetramethyl-hexadec-2-enoic acid 2-(3,7,11,15-tetramethyl-hexadec 2-enoyloxy)-phenyl ester. 5 Compound class 13 includes branched alcohols with the general formula: *l*l OH -m- -n where n+m=an integer from 0 to 9. Examples include: OH 3,7,11 -Trimethyl-dodecan- 1 -ol; 10 OH 3,7,11,15-Tetramethyl-hexadecan- 1 -ol (Dihydro phytol); and 15 OH 3,7,11,15,19-Pentamethyl-icosan-1-ol. Compound class 14 includes carboxylic acid esters with the general formula: * * O R' -m- -n 20 where n+m=an integer from 0 to 9; and where R' is, e.g., H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted. Examples include: 32 WO 2007/104790 PCT/EP2007/052457 0 Propionic acid 3,7,11,15-tetramethyl-hexadecyl ester (Dihydrophytyl propionate); 5 0 Hexadecanoic acid 3,7,11,15-tetramethyl-hexadecyl ester (Dihydrophytyl palmitate); 10 0 ° 0 Octadecanoic acid 3,7,11,15-tetramethyl-hexadecyl ester (Dihydrophytyl stearate); 15 0 Octadec-9-enoic acid 3,7,11,15-tetramethyl-hexadecyl ester (Dihydrophytyl oleate); 20 O Octadeca-9,12-dienoic acid 3,7,11,15-tetramethyl-hexadecnyl ester (Dihydrophytyl linoleate); 25 33 WO 2007/104790 PCT/EP2007/052457 O Octadeca-9,12,15-trienoic acid 3,7,11,15-tetramethyl-hexadecyl ester (Dihydrophytyl linolenate); 5 O Eicosa-5,8,11,14-tetraenoic acid 3,7,11,15-tetramethyl-hexadec-2-enyl ester (Dihydrophytyl aracidonate); 10 00 0 0 lOO O Succinic acid di-(3,7,11,15-tetramethyl-hexadecyl) ester (Di-dihydrophytyl-succinate); 0 0 0 15 Succinic acid (3,7,11-trimethyl-dodecyl) (3,7-dimethyl-octyl) ester; 34 WO 2007/104790 PCT/EP2007/052457 00 0 HO o 0 Ci(Tric ac-dihydrophytyl-ci tri-(3,7,11,15-tetramethyl-hexadecyl) esterte); (Tri-dihydrophytyl-citrate); 5 00 Benzoic acid 3,7,11,15-tetramethyl-hexadecyl ester (Dihydrophytyl bensoate); O0 OH 10 2-Hydroxy-benzoic acid 3,7,11,15-tetramethyl-hexadecyl ester (Dihydrophytyl salicylate); 0

NH

2 15 4-Amino-benzoic acid 3,7,11,15-tetramethyl-hexadecyl ester (Dihydrophytyl para-aminobenzoate); 0 Cyclopenta-1,3-dienecarboxylic acid 3,7,11,15-tetramethyl-hexadecyl ester 20 (Dihydrophytyl cyclopenta- 1,3-dienecarboxylate); 35 WO 2007/104790 PCT/EP2007/052457 0 Nicotinic acid 3,7,11,15-tetramethyl-hexadecyl ester (Dihydrophytyl nicotinate); 5 00 Furan-2-carboxylic acid 3,7,11,15-tetramethyl-hexadecyl ester (Dihydrophytyl 2-furoate); 10 and O Thiophen-2-carboxylic acid 3,7,11,15-tetramethyl-hexadecyl ester. 15 Compound class 15 includes carbamates with the general formula: * * O N R' -m- -n where n+m=an integer from 0 to 9; and R' is, e.g., H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted. 20 Examples include: 36 WO 2007/104790 PCT/EP2007/052457 Ethyl carbamic acid 3,7,11,15-tetramethyl-hexadecyl ester (Dihydrophytyl N-ethyl carbamate); 5 0O N Phenyl carbamic acid 3,7,11,15-tetramethyl-hexadecyl ester (Dihydrophytyl N-phenyl carbamate); O N OH 10 2-Hydroxy-phenyl carbamic acid 3,7,11,15-tetramethyl-hexadecyl ester (Dihydrophytyl N-2-hydroxy-phenyl carbamate); O Pyridin-4-yl carbamic acid 3,7,11,15-tetramethyl-hexadecyl ester 15 (Dihydrophytyl N-pyridin-4-yl carbamate); Furan-2-yl carbamic acid 3,7,11,15-tetramethyl-hexadecyl ester (Dihydrophytyl N-fyran-2-yl carbamate); and 20 Thiophen-2-yl carbamic acid 3,7,11,15-tetramethyl-hexadec-2-enyl ester (Dihydrophytyl N-thiphen-2-yl carbamate). 37 WO 2007/104790 PCT/EP2007/052457 Compound class 16 substitutes a halogen moiety for the hydroxy moiety in compound class 13. Halogen moieties include F, Cl, Br, and I. 5 Compound class 17 includes aryl ethers with the general formula: **O1Ar -m- -n where n+m=an integer from 0 to 9; and Ar is optionally substituted aryl (e.g., phenyl), exemplified by: 10 (3,7,11,15-Tetramethyl-hexadecyloxy)-benzene. Compound class 18 includes thio ethers with the general formula: * * SR' -m- -n 15 where n+m=an integer from 0 to 9; and where R' is, e.g., H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted. Examples include: 20 1 -Ethylsulfanyl-3,7,11,15-tetramethyl-hexadecane; S 1 -Hexadecylsulfanyl-3,7,11,15-tetramethyl-hexadecane; 25 38 WO 2007/104790 PCT/EP2007/052457 (3,7,11,15-Tetramethyl-hexadecylsulfanyl)-benzene; 5(3,7,11,15-Tetramethyl-hexadecylsulfanyl)-cyclopbenzenta- 1,3-diene; 5 5 -(3,7,11,1 5-Tetramethyl-hexadecylsulfanyl)-cyclopenta- 1, 3 -diene; 4-(3,7,11,15-Tetramethyl-hexadecylsulfanyl)-pyridine; 10 10 S 2-(3,7,11,15-Tetramethyl-hexadecylsulfanyl)-furan; and 2-(3,7,11,15-Tetramethyl-hexadecylsulfanyl)-thiophen. 15 Compound class 19 includes amines with the general formula: [*lm *l NR' -m -n I R" where n+m=an integer from 0 to 9; and where R' and R" independently are, 20 e.g., H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted. Some examples include: 39 WO 2007/104790 PCT/EP2007/052457 N L_. Diethyl-(3,7,11,15-Tetramethyl-hexadecyl)-amine; N 5 Ethyl-hexadecyl-(3,7,11,15-tetramethyl-hexadecyl)-amine; N 10 Dihexadecyl-(3,7,11,15-tetramethyl-hexadecyl)-amine; N Ethyl-phenyl-(3,7,11,15-tetramethyl-hexadecyl)-amine; and N 15 Diphenyl-(3,7,11,15-tetramethyl-hexadecyl)-amine. 40 WO 2007/104790 PCT/EP2007/052457 Compound class 20 includes compounds with the general formula: [n R" where n+m=an integer from 0 to 9; p+q=an integer from 0 to 9; and R' and R" independently are H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or 5 heteroaryl, each of which is optionally substituted. Examples include: 17,17,diethyl-2,6,10,14,20,24,28,32-octamethyl-tritriacontane; 10 13,13-Diethyl-2,6,10,16,20-pentamethyl-henicosa-2,6,19-triene; and [2-Ethyl-5,9,13,17-tetramethyl-2-(3,7,11,15-tetramethyl-hexadecyl) octadecane]-benzene. 15 41 WO 2007/104790 PCT/EP2007/052457 Compound class 21 includes compounds with the general formula: S-n R" R"' where n+m=an integer from 0 to 9; and R', R" and R"' independently are, e.g., H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is 5 optionally substituted, exemplified by: 3,3-Diethyl-6,10,14,18-tetramethyl-nonadecane; and 10 (2,2-Diethyl-,5,9,13,17-tetramethyl-octadecyl)-benzene. Compound class 22 are carboxylic acids having the general formula: *l * OH 15

-

-n where n+m= and integer from 0 to 13, exemplified by: OH 3,7,11,15-Tetramethyl-hexadecanoic acid 20 (Phytanic acid). 42 WO 2007/104790 PCT/EP2007/052457 Compound class 23 includes amides of the general formula: * * N' m N R " where n+m=an integer from 0 to 9; and R' and R" independently are, e.g., H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is 5 optionally substituted. Examples include: 0 N, 3,7,11,15-Tetramethyl-hexadecanoic acid diethylamide (Phytanic acid diethylamide); 10 0 N 3,7,11,15-Tetramethyl-hexadecanoic acid hexadecylamide (Phytanic acid hexadecylamide); and 15 0 N 3,7,11,15-Tetramethyl-hexadecanoic acid phenylamide. Compound class 24 includes carboxylic acid esters with the general formula: 0 /R' 20 m -n where n+m=an integer from 0 to 9; and R' is, e.g., alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted, exemplified by: 43 WO 2007/104790 PCT/EP2007/052457 o 3,7,11,15-Tetramethyl-hexadecanoic acid ethyl ester (Phytanic acid ethyl ester); 0 5 0 3,7,11,15-Tetramethyl-hexadecanoic acid octadecen-9-yl ester (Phytanic acid oleyl ester); 10 3,7,11,15-Tetramethyl-hexadecanoic acid phenyl ester (Phytanic acid phenyl ester); O 15 3,7,11,15-Tetramethyl-hexadecanoic acid pyridin-4-yl ester (Phytanic acid pyridin-4-yl ester); 0 0 3,7,11-Trimethyl-dodecanoic acid 4-(3,7,11-trimethyl-dodecanoyloxy)-butyl 20 ester; 44 WO 2007/104790 PCT/EP2007/052457 O 0 3,7,11,15-Tetramethyl-hexadecanoic acid 4-(3,7-dimethyl-octanoyloxy)-butyl ester; 5 and O O 3,7,11,15-Tetramethyl-hexadecanoic acid 2-(3,7,11,15-tetramethyl 10 hexadecanoyloxy)-phenyl ester. Compound class 25 includes compounds with the general formula: [ l[ \OH -m- -n 15 where n+m=an integer from 0 to 9, exemplified by: OH [2-Methyl-2-(4,8,12-trimethyl-tridecyl)-cyclopropyl] -methanol. 20 Compound class 26 includes compounds with the general formula: 45 WO 2007/104790 PCT/EP2007/052457 m H -M m - - O Br Br where n+m=an integer from 0 to 9, exemplified by: OH Br Br [2,2-Dibromo-3-methyl-3-(4,8,12-trimethyl-tridecyl)-cyclopropyl]-methanol. 5 Compound class 27 includes compounds with the general formula: [ *l[ "OH m - -n where n+m=an integer from 0 to 9, exemplified by: 10 OH [2,2,3-Trimethyl-3-(4,8,12-trimethyl-tridecyl)-cyclopropyl]-methanol. 15 Compound class 28 includes compounds with the general formula: OH lA[F Br -m -n where n+m=an integer from 0 to 9, exemplified by: OH Br F 20 2-Bromo-3-fluoro-3,7,11,15-tetramethyl-hexadecan- 1-ol. 46 WO 2007/104790 PCT/EP2007/052457 Compound class 29 are compounds with the general formula: SOH -m -n F 5 where n+m=an integer from 0 to 9, exemplified by: OH F 3-Fluoro-2-iodo-3,7,11,15-tetramethyl-hexadecan- 1 -ol. 10 Compound class 30 include compounds having the general formula: OH -m -n where n+m=an integer from 0 to 9, exemplified by: OH 15 OH 2-lodo-3,7,11,15-tetramethyl-hexadecane- 1,3-diol. Compound class 31 includes compounds with the general formula: OH ABr Br 20 m n where n+m=an integer from 0 to 9, exemplified by: 47 WO 2007/104790 PCT/EP2007/052457 OH Br 2,3-Dibromo-3,7,11,15-tetramethyl-hexadecan- 1-ol. 5 Compound class 32 are compounds with the general formula: [ *m[ OH m

-

-n _ z 0H OO where n+m=an integer from 0 to 9, exemplified by: OH 10 3-Hydroxymethyl-2-methyl-2-(4,8,12-trimethyl-tridecyl) cyclopropanecarboxylic acid ethyl ester. Compound class 33 includes compounds with the general formula: [ *m[ ''OH -m - n O 15 where n+m=an integer from 0 to 9, exemplified by: OOH [3-Methyl-3-(4,8,12-trimethyl-tridecyl)-oxiranyl]-methanol. 20 48 WO 2007/104790 PCT/EP2007/052457 Compound class 34 are compounds having the general formula: R' \N-R" [ *l [ *1 O OH -m -n where n+m=an integer from 0 to 9; and where R' and R" independently are, e.g., H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of 5 which is optionally substituted. Examples include: N OH OH 2-Diethylamino-3,7,11,15-tetramethyl-hexadecane- 1,3-diol; N OH OH 10 2-Diphenylamino-3,7,11,15-tetramethyl-hexadecane- 1,3-diol; N OH OH 15 2-Hexadecylamino-3,7,11,15-tetramethyl-hexadecane- 1,3-diol; and NN OH OH 3,7,11,15-Tetramethyl-2-(pyridin-4-ylamino)-hexadecane- 1,3-diol. 49 WO 2007/104790 PCT/EP2007/052457 Compound class 35 are compounds with the general formula: S, R * *H OH 5 -m -n where n+m=an integer from 0 to 9; and where R' is, e.g., H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted, exemplified by: OH OH 10 2-Ethylsylfanyl-3,7,11,15-tetramethyl-hexadecane- 1,3-diol; OH OH 15 2-Hexadecylsylfanyl-3,7,11,15-tetramethyl-hexadecane- 1,3-diol; S OH OH 3,7,11,15-Tetramethyl-2-phenylsulfanyl-hexadecane- 1,3-diol; 50 WO 2007/104790 PCT/EP2007/052457 S N OH OH 3,7,11,15-Tetramethyl-2-(pyridin-4-yl-sylfanyl)-hexadecane-1,3-diol; and S OH OH 5 2-(Furan-2-ylsylfanyl)-3,7,11,15-Tetramethyl-hexadecane- 1,3-diol. Compound class 36 are compounds with the general formula: [ *l[ ' N -m- -n N where n+m=an integer from 0 to 9, exemplified by: 10 N 1-(3,7,11,15-Tetramethyl-hexadec-2-enyl)-piperazine. 15 Compound class 37 are compounds with the general formula: 51 WO 2007/104790 PCT/EP2007/052457 N R' 0 where n+m=an integer from 0 to 9; and where R' is, e.g., H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted, exemplified by: 5 N N O 2-Methyl- 1- [4-(3,7,11,15-tetramethyl-hexadec-2-enyl)-piperazin- 1 -yl] -propane 1-one; N N 10 O 1-[4-(3,7,11 -Trimethyl-dodeca-2,6,10-trienyl)-piperazin- 1 -yl] -heptadecan- 1 one; N N YO 15 0 Phenyl- [4-(3,7,11,15-tetramethyl-hexadec-2-enyl)-piperazin- 1 -yl]-methanone; and 52 WO 2007/104790 PCT/EP2007/052457 N O N 0 Furan-2-yl-[4-(3,7,11-trimethyl-dodeca-2,6,10-trienl)-piperazin-1-yl] methanone. 5 Compound class 38 are compounds with the general formula: N N,'R" O where n+m=an integer from 0 to 9; and where R" is, e.g., H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is optionally 10 substituted, exemplified by: N N N 0 4-(3,7,11,15-Tetramethyl-hexadec-2-enyl)-piperazine- 1-carboxylic (3-methyl butyl)-amide; 15 N N<N 0 4-(3,7,11-Trimethyl-dodeca-2,6,19-trienyl)-piperazine- 1-carboxylic acid cyclohexylamide; and 53 WO 2007/104790 PCT/EP2007/052457 N N N 01 4-(3,7,11-Trimethyl-dodeca-2,6,10-trienyl)-piperazine- 1-carboxylic acid pyridin-2-ylamide. 5 Compound class 39 are compounds with the general formula: *m N N N'.R"' S where n+m=an integer from 0 to 9; and where R'" is, e.g., H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted, exemplified by: 10 N N N S 4-(3,7,11,15-Tetramethyl-hexadec-2-enyl)-piperazine- 1-carbothioic acid propylamide; and N N N SI 15 4-(3,7,11-Trimethyl-dodeca-2,6,10-trienyl)-piperazine- 1-carbothioic acid pyridin-2-ylamide. 54 WO 2007/104790 PCT/EP2007/052457 Compound 40 includes compounds with the general formula: [*lm * N -m- -n N where n+m=an integer from 0 to 9; exemplified by: N 5 1-(3,7,11,15-Tetramethyl-hexadecyl)-piperazine. Compound class 41 are compounds having the general formula: * * N N R' 10 O where n+m=an integer from 0 to 9; and where R' is, e.g., H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted, exemplified by: N N 15 O 2-Methyl- 1- [4- (3,7,11,15-tetramethyl-hexadecyl)-piperazin- 1 -yl] -propane- 1 one; 55 WO 2007/104790 PCT/EP2007/052457 N N 0 1-[4-(3,7,11 -Trimethyl-dodeca-6,10-dienyl)-piperazin-1-yl]-heptadecan- 1-one; N N 5 0O Phenyl-[4-(3,7,11,15-tetramethyl-hexadecyl)-piperazin-1l-yl]-methanone; and N O N 1 0 Furan-2-yl-[4-(3,7,11-trimethyl-dodeca-6,10-dienl)-piperazin-1-yl]-methanone. 10 Compound class 42 are compounds with the general formula: no NN ' ,R" 0 where n+m=an integer from 0 to 9; and where R" is, e.g., H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is optionally 15 substituted, exemplified by: 56 WO 2007/104790 PCT/EP2007/052457 N N N 0 4-(3,7,11,15-Tetramethyl-hexadecyl)-piperazine- 1-carboxylic (3-methyl-butyl) amide; N N N 0 5 4-(3,7,11-Trimethyl-dodeca-6,10-dienyl)-piperazine- 1-carboxylic acid cyclohexylamide; and N O N N N,, NNN 01 10 4-(3,7,11-Trimethyl-dodecyl)-piperazine- 1-carboxylic acid pyridin-2-ylamide. Compound class 43 are compounds with the general formula: [ * * N N NR S 15 where n+m=an integer from 0 to 9; and where R'" is, e.g., H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted, exemplified by: 57 WO 2007/104790 PCT/EP2007/052457 N N S 4-(3,7,11,15-Tetramethyl-hexadecyl)-piperazine- 1-carbothioic acid propylamide; and N N 5 4-(3,7,11,15,19-Pentamethyl-icosyl)-piperazine- 1-carbothioic acid pyridin-2 ylamide. 10 Compound class 44 includes ketones and aldehydes having the general formulas: 15 or 58 WO 2007/104790 PCT/EP2007/052457 [ *lm' *lR' -m- -n where n+m is an integer from 0 to 9; and where R' can be, e.g., H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted. Particular compounds include: 5 0 6,10-Dimethyl-undeca-5,9-dien-2-one (Geranyl acetone); 10 6,10,14-Trimethyl-pentadeca-5,9,13-trien-2-one (Farnesyl acetone); 15 9,13,17,21-Tetramethyl-docos-8-en-5-one; 0 3,7,11-Trimethyl-dodeca-2,6,10-trienal (Farnesal); 20 0 2OO 3,7-Dimethyl-oct-6-enal (Citronellal); 59 WO 2007/104790 PCT/EP2007/052457 0 3,7-Dimethyl-octa-2,6-dienal (Citral); 5 1-Furan-2-yl-5,9,13-trimethyl-tetradeca-4,8,12-trien-1-one; and 0 o10 2,6,10,18,22,26,30-Heptamethyl-hentriaconta-2,6,10,17-tetraen-14-one. Compound class 45 are compounds having the general formula: yR' * *O m - 15 where n+m= an integer from 0 to 9; and where R' can be, e.g., H; alkyl, alkenyl, alkynyl, cycloalkyl, each of which is optionally substituted (e.g., with halogen);, exemplified by: O 20 6-Methoxy-2,5,7,8-tetramethyl-2-(4,8,12-trimethyl-tridecyl)-chroman; and 60 WO 2007/104790 PCT/EP2007/052457 F H F O 6-Difluoromethoxy-2,5,7,8-tetramethyl-2-(4,8,12-trimethyl-tridecyl)-chroman. Compound Class 46 are compounds having the general formula: 10 [ OR' 10 - ~ ~ - - n where n+m= an integer from 0 to 9; and where R' can be H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl,aryl, or heteroaryl, each of which is optionally 15 substituted, exemplified by : CH3 CHz C H HC OH

H

3 CC 20 It is to be understood that any of the compounds provided herein may contain chiral centers. Such chiral centers may be of either the (R) or (S) configuration, or may be a mixture thereof. Thus, the compounds provided herein may be enantiomerically pure, or be stereoisomeric or diastereomeric mixtures. It is to be understood that the chiral centers of the compounds provided herein may undergo epimerization in vivo. As 25 such, one of skill in the art will recognize that administration of a compound in its (R) form is equivalent, for compounds that undergo epimerization in vivo, to administration of the compound in its (S) form. Compounds of the invention can be prepared by the methods set forth in Figure 1A-1E. Starting materials, including isoprenoids, isoprenoid alcohols, polyprenols, 30 terpenes, terpenoids, and terpenols, are available commercially from, e.g., Sigma Aldrich (St. Louis, MO). 61 WO 2007/104790 PCT/EP2007/052457 2. Treating, Preventing, Ameliorating Symptoms of, or Delaying the Onset of an Autoimmune Condition The invention provides methods, compounds, and compositions containing the compounds for treating, preventing, ameliorating one or more symptoms of, or delaying 5 the onset of an autoimmune condition in a mammal. Methods for treating, preventing, delaying the onset of, or ameliorating one or more symptoms of an autoimmune condition include administering a compound that increases the level of NADPH oxidase activity in the mammal, e.g., an NADPH oxidase activator. For example, a compound that increases a cell's production of reactive oxygen species can be administered to a 10 mammal with arthritis. The invention further provides methods for the use of a compound that increases the level of NADPH oxidase activity in a mammal for the manufacture of a medicament for treating, preventing, delaying the onset of, or ameliorating one or more symptoms of an autoimmune condition. 15 Such autoimmune conditions include, without limitation, arthritis (e.g., rheumatoid arthritis (RA)), multiple sclerosis (MS), inflammatory bowel disease, Crohn disease, lupus, autoimmune uveitis, type I diabetes, bronchial asthma, septic arthritis induced with staphylococci or streptococci, and cardiovascular disease involving vasculitis. 20 Such compounds that increase NADPH oxidase activity can include any of the compoundsdescribed in the compound classes set forth above. The compounds described herein can be administered in any standard form using any standard method (e.g., in the form of a composition, e.g., a pharmaceutical composition). For example, compounds that increase NADPH oxidase activity can be 25 in the form of tablets or capsules (e.g., time-release capsules) that are taken orally. Alternatively, the compounds can be in a liquid form and can be taken orally or by injection. The compounds also can be in the form of suppositories. Further, compounds that increase NADPH oxidase activity can be in the form of creams, gels, and foams that can be applied to the skin. In addition, the compounds can in the form 30 of an inhalant that is applied nasally. The compounds may be administered intra dermally, intra-peritoneally, orally, or intra-nasally. Compounds that increase NADPH oxidase activity can be administered at any dose that is sufficient to increase NADPH oxidase activity in cells that have low activity. Such doses can be taken over a period of years to prevent and/or delay the 62 WO 2007/104790 PCT/EP2007/052457 progression of the autoimmune condition or to reverse the progression of the autoimmune condition. Doses can be selected based on the effectiveness and toxicity of the particular compound using standard pharmacology techniques. The methods of the invention can be applied to a wide range of subjects, e.g., 5 mammals such as humans, non-human primates (e.g., monkeys), horses, cattle, pigs, sheep, goats, dogs, cats, rabbits, guinea pigs, hamsters, rats, and mice. In some embodiments, the subject can be a subject in need thereof (e.g., a subject identified as being in need of such treatment). Identifying a subject in need of such treatment can be in the judgment of a subject or a health care professional and can be subjective (e.g. 10 opinion) or objective (e.g. measurable by a test or diagnostic method). In some embodiments, the subject can be a mammal. In certain embodiments, the subject is a human. In one in vivo approach, a compound or pharmaceutical composition described herein is administered to the subject, e.g., a mammal, such as a mammal suspected of 15 suffering from, or suffering from, an autoimmune condition. Generally, the compounds of the invention will be suspended in a pharmaceutically-acceptable carrier (e.g., physiological saline) and administered orally or transdermally or injected (or infused) intravenously, subcutaneously, intramuscularly, intraperitoneally, intrarectally, intravaginally, intranasally, intragastrically, intratracheally, or intrapulmonarily. They 20 can be delivered directly to an appropriate affected tissue. The dosages of the inhibitory compounds and supplementary agents to be used depend on the choice of the route of administration; the nature of the formulation; the nature of the patient's illness; the subject's size, weight, surface area, age, and sex; other drugs being administered; and the judgment of the attending physician. Suitable 25 dosages are generally in the range of 0.0001-100.0 mg/kg. Wide variations in the needed dosage are to be expected in view of the variety of compounds and supplementary agents available and the differing efficiencies of various routes of administration. For example, oral administration would be expected to require higher dosages than administration by i.v. injection. Variations in these dosage levels can be 30 adjusted using standard empirical routines for optimization as is well understood in the art. Administrations of compounds and/or supplementary agents can be single or multiple (e.g., 2-, 3-, 4-, 6-, 8-, 10-, 20-, 50-,100-, 150-, or more fold). The invention will be further described in the following examples, which do not limit the scope of the invention described in the claims. 63 WO 2007/104790 PCT/EP2007/052457 EXAMPLES Example 1 - Animals Rat (Rattus norvegicus) strains used in the following experiments included the 5 DA and LEW. 1F strains, which are highly susceptible to PIA and EAE, and the E3 strain, which is PIA and EAE-resistant (Bergsteinsdottir et al. (2000) J Immunol 164: 1564-8; Vingsbo et al. (1996) Am JPathol 149: 1675-83). DA, LEW.1F and E3 rats were obtained from Zentralinstitut flir Versuchstierzucht, Hannover, Germany; DA rats purchased from Harlan Netherlands were also used. 10 The term DA.Ncfl DA rats designates DA rats carrying the Ncfl DA allele with impaired NADPH oxidase capacity and the term DA.Ncfl E3 rats designates DA rats carrying the Ncfl E3 allele with functional NADPH oxidase capacity (Olofsson & Holmdahl (2003) Scand J Immunol 58:155-164). All animals were kept in animal facilities that have climate-controlled 15 environments with 12-hour light/dark cycles. Rats were housed in polystyrene cages containing wood shavings and were fed standard rodent chow and water ad libitum. Rats were free from common pathogens, including the Sendai virus, Hantaan virus, coronavirus, reovirus, cytomegalovirus, and Mycoplasma pulmonis. Disease was induced in all rats at the age of 6-12 weeks. Arthritis development 20 was monitored with a macroscopic scoring system of the four limbs ranging from 0 to 15 (1 point for each swollen or red toe, 1 point for midfoot digit or knuckle, 5 points for a swollen ankle). The scores of the four paws were added yielding a maximum total score of 60 for each rat. 25 Example 2 - Compounds Compound 1: Phytol (3,7,11,15-Tetramethyl-2-hexadecen- 1 -ol) OH was obtained from Sigma Aldrich. 30 64 WO 2007/104790 PCT/EP2007/052457 Compound 2: Farnesol (3,7,11 -Trimethyl-2,6,10-dodecatrien- 1 -ol) OH was obtained from SigmaAldrich. 5 Compound 3: Geranylgeraniol (3,7,11,15-Tetramethyl-hexada- 2,6,10,14-tetraen- 1 -ol) O H was obtained from SigmaAldrich. Compound 4: Farnesyl acetate (Acetic acid 3,7,11-trimethyl-dodeca-2,6,10-trienyl 10 ester) 0 was obtained from Fluka. Compound 5: Phytyl acetate (Acetic acid 3,7,11,15-tetra-metyl-hexadec-2-enyl-ester) 0 15 was synthesized according to Figure 1A. Compound 6: Di-hydro-phytol (3,7,11,15-Tetramethyl-hexadecan- 1-ol) 'j OH 20 was synthesized according to Figure lB. 65 WO 2007/104790 PCT/EP2007/052457 Compound 7: Di-hydro-phytyl acetate (Acetic acid 3,7,11,15-tetramethyl-hexadecyl ester) 0

CH

3 was synthesized according to Figure lB. 5 Compound 8: 6-Difluoromethoxy-2,5,7,8-tetramethyl-2-(4,8,12-trimethyl-tridecyl) chroman F HF O was synthesized according to Figure 1E. 10 Compound 9: Isophytol (3,7,11,15-Tetramethyl- 1-hexadecen-3-ol) COH CH3 CH3 HzC OH

H

3 C was obtained from Sigma Aldrich. 15 Example 3 - Oxidative burst assay of granulocytes in vitro The human myeloma cell line HL-60 (ATCC, CC1-240) was cultured in D-MEM (Gibco, Paisley, UK) complemented with 10% fetal calf serum and Penicillin Streptomycin. The cells were differentiated to granulocytes by culture in presence of 20 1.25% dimethylsulfoxide (DMSO; Sigma Aldrich Inc., Milwaukee, WI) for six days. Before assaying the cells were washed and resuspended in PBS to a concentration of 10 7 cells/ml. Oxidative burst assay of granulocytes in vitro 25 NADPH activating oils were tested for oxidative burst inducing capacity 66 WO 2007/104790 PCT/EP2007/052457 according to a previously described method (Dahlgren and Karlsson (1999) J Immunol Methods 232: 3-14). In order to get the oils solubilized, they were diluted at 2% concentration in 3-cyclodextrin (Sigma Aldrich) (10 mM in PBS) in PBS. 3 cyclodextrin by itself or the used oil control had no stimulating effect on ROS 5 production. Briefly, 5 pl of resuspended oils were added into 96-well plates containing 5x10 5 cells/well in a total volume of 200 pl PBS/well (final concentration isoluminol 50 pg/ml; Sigma Aldrich) and horse radish peroxidase (type II 2,5 U/ml; Sigma Aldrich). Samples were gently mixed and the data collection was initiated immediately. Extra cellular ROS production was followed at 37 0 C as produced luminescence signal 10 (FluoStar Optima, BMG Labtechnologies, Offenburg, Germany) and presented as maximal relative signal during a measurement period of 50 minutes. The NADPH activators compound 1 (phytol), compound 2 (farnesol) and compound 3 (geranylgeraniol) give strong ROS production from the HL60 cells. These compounds are all non arthritogenic but have arthritis ameliorating effects. Pristane is a 15 potent arthritis inducing compound that does not induce ROS production in HL60 cells. Extra-cellular ROS production was measured with an isoluminol assay on HL-60 cells after in vitro stimulation with compound 1 (phytol) (*), compound 2 (farnesol) (0), compound 3 (geranylgeraniol) (A) or pristane (0). (Figure 2). 20 Example 4 - Compound 1 (phytol) increases oxidative burst in vivo Phytol restores the oxidative burst defect in vivo. Oxidative burst response to PMA stimulation in vitro in spleen granulocytes taken 5 days after s.c. phytol injection in DA.Ncfl 1A rats (200 pl) compared to naive DA.Ncfl 1A and DA.NcflE 3 (n=5) (Figure 3). 25 Treatment of rats with impaired NADPH oxidase capacity, DA.Ncfl 1A rats, with injection of compound 1 restores to NADPH oxidase capacity to a level comparable to the level of NADPH oxidase capacity in rats with a functional oxidative burst, fE3 DA.Ncfl E3 rats. 30 Example 5 - Biodistribution DA rats originating from Harlan Netherlands (N=4 rats per group) injected with compound 1 (phytol) mixed with radiolabelled compound 1 (phytol) (Moravek 67 WO 2007/104790 PCT/EP2007/052457 Biochemicals, CA) to a total volume of 200pl at 167pCi/rat with 3 H-Phytol. At sacrifice at day 2, 4, 8, 11 and 17, respectively, inguinal lymph nodes, spleen, heart, thymus, kidney, liver, lung, adipose tissue, muscle, injection site tissue and blood were collected in equal amount of saline solution in pre-weight tubes (blood with heparin to prevent 5 coagulation). The tissues were homogenized and mixed with ready-safe scintillation liquid (Beckman Coulter, CA). Biodistribution was estimated as relative CPM per gram tissue. Besides the large fraction of phytol (> 90%, not shown) that remained as a depot in the injection site, the draining lymph nodes were the primary tissue for accumulation of phytol. The 10 distribution of phytol to the inguinal lymph nodes showed highest accumulation more than one week after injection and showed a decrease after two weeks (Figure 4). It was at this level determined that phytol was distributed primarily to the cortical regions as well as close to the sinusoidal space of the draining lymph nodes. Moreover, the staining seemed to appear in-between cells or in the cell membrane, i.e. not 15 intracellular. Example 6 - Treatment of PIA with compound 1 (phytol) Pristane induced arthritis (PIA) was induced in the rats by a subcutaneous (s.c.) injection at the base of the tail with 200 pl of pristane. 20 Compound 1 (phytol) inhibits development of arthritis. A significant preventive effect of compound 1 (phytol) on PIA can be seen in DA.Ncfl DA rats. Compound 1 (phytol) was injected s.c. day -5 prior to pristane injection (untreated control (A) and compound 1 (phytol) (A)). (Figure 5). 25 Example 7 - Treatment of established PIA with compound 1 (phytol) Pristane induced arthritis (PIA) was induced in the rats by an subcutaneous (s.c.) injection at the base of the tail with 200 pl of pristane. Therapeutic treatments were administered s.c. or intra peritoneal (i.p.; 200 pl) after onset of disease in the acute or chronic phase (Figure 6). 30 Injection of compound 1 (phytol) ameliorates disease in the acute phase of arthritis (Figure 6A). A significant therapeutic effect of compound 1 (phytol) can be seen in acute phase of PIA in DA.Ncfl DA rats after two injections (200 Pl) with 5 days in between starting at the estimated peak of disease (day 22). 68 WO 2007/104790 PCT/EP2007/052457 Cartilage destruction is decreased after injection of compound 1 (phytol) (Figure 6B). Sera were taken day 38 and analyzed for COMP levels as a measurement of cartilage destruction. Results are presented as circles, where every circle represents one individual and filled circles represent rats with a mean reduction in score after day of 5 first treatment (day 22). Lines represent mean value. Compound 1 (phytol) decreases arthritis severity in the chronic phase of arthritis (Figure 6C). Compound 1 (phytol) was injected i.p. twice (200 pl), starting day 70 after pristane injection in DA.Ncfl D A rats with three days between treatments (control (A) and compound 1 (phytol) s.c. (A)). 10 The preventive effect of compound 1 (phytol) is not dependent on genetic background (Figure 6D). An arthritis preventing effect of compound 1 (phytol) when injected (200 pl s.c.) 5 days before induction of PIA could also be seen in another arthritis susceptible strain i.e. the Lewis.IF rat, (control (A) and compound 1 (phytol) s.c. (A)). 15 Compound 1 (phytol) has an arthritis ameliorating effect also in rats with a functional oxidative burst (Figure 6E). Rats heterozygous for the functional Ncfl (NcflE 3 ) allele but with an increased arthritis susceptibility locus (Pia3) introduced in the genome on chromosome 6 (Olofsson et al. (2003) Genomics 82: 652-9). Compound 1 (phytol) was injected i.p. (200 pl) at the estimated peak of disease (control 20 (A) and compound 1 (phytol) (A)). Example 8 - Compound 1 (phytol) suppresses CIA with oil adjuvant Collagen induced arthritis (CIA) was induced by an s.c. injection of 100 pl of rat collagen type II (CII; 100pg/rat-150pg/rat), emulsified in incomplete Freund's adjuvant 25 (IFA; Sigma Aldrich) (Figure 7). Compound 1 (phytol) prevents collagen-induced arthritis in DA.Ncfl D A rats (Figure 7A). Effect of s.c. administration of phytol (200 pl) 5 days. Compound 1 (phytol) decreases anti-CII antibody levels in serum (Figure 7B). At day 27 after immunization, sera were taken and analyzed for anti-CII IgG levels 30 (n=7). Titers are relative to pooled positive sera (units). 69 WO 2007/104790 PCT/EP2007/052457 Example 9 - Compound 1 (phytol) suppresses CIA without oil adjuvant Non oil collagen induced arthritis (NOCIA) was induced by emulsifying rat CII (300pg) in a mixture of LPS (50 pg; Sigma Aldrich), CPG (5'-TCC ATG ACG TTC CTG ACG TT-3'; SEQ ID NO: 1) (45 pg; MWG-Biotech AG, Ebersberg, Germany) 5 and alum (6 mg; Sigma Aldrich) and injected s.c. in a total volume of 300 Pl. Compound 1 (phytol) reduces arthritis severity also in NOCIA (Figure 8A), an arthritis model induced without involvement of oil. Preventive effect on arthritis of phytol injection (200 pl s.c.) five days prior to induction of NOCIA in DA.Ncfl D A rats, (control (A) and compound 1 (phytol) (A)). 10 Delayed type hypersensitivity (DTH) response is abrogated after compound 1 (phytol) injection (Figure 8B). Day 67 after NOCIA immunization the immune system was challenged by an injection of CII in the ear. Following increase in ear volume was measured and compared to control ear (control n=7 and compound 1 (phytol) n=8). 15 Example 10 - Arthritis treatment with compound 5 (phytyl acetate) Pristane induced arthritis (PIA) was induced in the rats by a subcutaneous (s.c.) injection at the base of the tail with 150 pl of pristane. Treatments with compound 1 (phytol) or compound 5 (phytyl acetate) were administered to DA.Ncfl D A rats as 100 Pl subcutaneous injections in the neck at day 8 and 10 after arthritis induction (untreated 20 control (0), compound 1 (phytol) (*) and compound 5 (phytyl acetate) (A)) (Figure 9). Treatment with compound 5, which is derivatized with a functional moiety, a carboxylic acid ester, gives a therapeutic effect comparable to the therapeutic effect of the un-derivatized compound 1. 25 Example 11 - Arthritis treatment with compound 8 Pristane induced arthritis (PIA) was induced in the rats by a subcutaneous (s.c.) injection at the base of the tail with 150 pl of pristane. Treatments with compound 8 or compound 1 (phytol) were administered to DA.Ncfl D A rats as 100 pl subcutaneous 30 injections in the neck at day 8 and 10 after arthritis induction, (untreated control (0), compound 1 (phytol) (*) and compound 8 (A)) (Figure 10). 70 WO 2007/104790 PCT/EP2007/052457 Example 12 - Arthritis treatment with compound 2 (farnesol) and compound 4 (farnesylacetate) Pristane induced arthritis (PIA) was induced in the rats by a subcutaneous (s.c.) 5 injection at the base of the tail with 150 pl of pristane. Treatments with compound 2 (farnesol) or compound 4 (farnesylacetate) were administered to DA.Ncfl DA rats as 100 pl subcutaneous injections in the neck at day 8 and 10 after arthritis induction, (untreated control (0), compound 2 (farnesol) (0) and compound 4 (farnesylacetate) (A)) (Figure 11). 10 Treatment with compound 4, which is derivatized with a functional moiety, a carboxylic acid ester, gives a therapeutic effect comparable to the therapeutic effect of the un-derivatized compound 2. Example 13 - Arthritis treatment with compound 1 (phytol), compound 6 (di-hydro 15 phytol, compound 5 (phytyl acetate), and compound 7 (di-hydro-phytyl acetate Pristane induced arthritis (PIA) was induced in the rats by a subcutaneous (s.c.) injection at the base of the tail with 150 pl of pristane. Treatments with compound 1 (phytol), compound 6 (di-hydro-phytol, compound 5 (phytyl acetate), or compound 7 20 (di-hydro-phytyl acetate were administered to DA.Ncfl D A rats as 100 pl subcutaneous injections in the neck at day 8 and 10 after arthritis induction, (untreated control (0), compound 1 (phytol) (*), compound 6 (di-hydro-phytol (0), compound 5 (phytyl acetate) (A) or compound 7 (di-hydro-phytyl acetate (0)) (Figure 12). Treatment with compound 6 and compound 7, which are compounds comprising 25 saturated isoprenoid units, gives a therapeutic effect comparable to the therapeutic effects of compound 1 and compound 5 which comprise one unsaturated isoprenoid unit. Example 14 - Arthritis treatment with oral administration of compound 1 (phytol) 30 Pristane induced arthritis (PIA) was induced in the rats by an subcutaneous (s.c.) injection at the base of the tail with 150 pl of pristane. Treatments of DA.Ncfl DA rats with compound 1 (phytol) mixed in the food for continuous uptake compared with 71 WO 2007/104790 PCT/EP2007/052457 Omega3 fatty acids, (untreated control (0), Omega3 fatty acid (0), phytol 1% daily (*), phytol 1% every 2'nd day (A), or phytol 1% initiated day 7 after arthritis induction (0)) (Figure 13). All three regimes of oral treatment with compound 1 (phytol) reduced the 5 severity of arthritis in the animals. Treatment with omega3 fatty acids had no effect on the severity of arthritis. Example 15 - Arthritis treatment with oral administration of compound 5 (phytyl acetate) 10 Pristane induced arthritis (PIA) was induced in the rats by an subcutaneous (s.c.) injection at the base of the tail with 150 pl of pristane. Treatments of DA.Ncfl D A rats with compound 5 (phytyl acetate) mixed in the food for daily uptake, (untreated control (0), compound 1 (phytol) 1% daily (*), or compound 5 (phytyl acetate) 1% daily (A)) (Figure 14). 15 Oral treatment with compound 5 (phytyl acetate) was equally effective as oral treatment with compound 1 (phytol) in reducing the severity of arthritis. Example 16 - Oxidative burst assay of granulocytes in vitro The human myeloma cells line HL-60 (ATCC, CC1-240) was cultured in D 20 MEM (Gibco, Paisley, UK) complemented with 10% fetal calf serum and Penicillin Streptomycin. The cells were differentiated to granulocytes by culture in presence of 1,25% dimethylsulfoxide (DMSO; Sigma Aldrich Inc., Milwaukee, WI) for six days. Before assaying the cells were washed and resuspended in PBS to a concentration of 107 cells/ml. 25 Oxidative burst assay of granulocytes in vitro NADPH activating oils were tested for oxidative burst inducing capacity according to a previously described method (Dahlgren and Karlsson (1999) J Immunol Methods 232: 3-14). In order to get the oils soluble they were diluted at 2% 30 concentration in 3-cyclodextrin (Sigma Aldrich) (10 mM in PBS) in PBS. 3 cyclodextrin by itself or the used oil control had no stimulating effect on ROS production. Briefly, 5 pl of resuspended oils were added into 96-well plates containing 72 WO 2007/104790 PCT/EP2007/052457 5x10 5 cells/well in a total volume of 200 pl PBS/well (final concentration isoluminol 50 pg/ml; Sigma Aldrich) and horseradish peroxidase (type II 2,5 U/ml; Sigma Aldrich). Samples were gently mixed and the data collection was initiated immediately. Extra cellular ROS production was followed at 37 0 C as produced luminescence signal 5 (FluoStar Optima, BMG Labtechnologies, Offenburg, Germany) and presented as maximal relative signal during a measurement period of 50 minutes. The NADPH activators compound 1 (phytol), compound 2 (farnesol) and compound 9 (isophytol) give strong ROS production from the HL60 cells. Extra cellular ROS production was measured with an isoluminol assay on HL-60 cells after in 10 vitro stimulation with compound 1 (phytol) (*), compound 2 (farnesol) (A) or compound 9 (isophytol) (0) (see Figure 15). Example 17 - Arthritis treatment by oral savage with compound 1 (phytol) at 1.6 or 2.3 g/kg/day 15 Pristane induced arthritis (PIA) was induced in the rats by a subcutaneous (s.c.) injection at the base of the tail with 200 pl of a 50% mixture of pristane/hexadecane. Treatments with compound 1 (phytol) at 1.6 or 2.3 g/kg/day administered to DA.Ncfl D A rats by oral gavage given by dosing every second day with compound 1 (phytol) 1.6mg/kg/every second day (*), compound 1 (phytol) 3.2 mg/kg/every second day (A) 20 or untreated control (0). Both doses of compound 1 (phytol) given by oral gavage have potent arthritis ameliorating effect. No adverse effect of the high doses given was observed, either by macroscopically observations or at postmortem dissection examination (see Figure 16). 25 Example 18 - Arthritis treatment with oral administration of compound 1 (phytol) in comparison with fenofibrate Fenofibrate (propan-2-yl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoate; Sigma-Aldrich) is known to be an antilipemic agent. It has been suggested that fenofibrate suppresses the development of arthritis by inhibition of NF-kappa B 30 signaling. See, e.g., Okamoto et al. CLIN EXP RHEUMATOL 23 (3): 323-330 MAY JUN 2005. Pristane induced arthritis (PIA) was induced in the rats by a subcutaneous (s.c.) injection at the base of the tail with 200 pl of a 50% mixture of pristane/hexadecane. 73 WO 2007/104790 PCT/EP2007/052457 Treatments of DA.Ncfl D A rats with compound 1 (phytol) or compound 9 (isophytol) mixed in the food for continuous uptake compared with fenofibrate, (compound 1 (phytol) 500 mg/kg/day (*), compound 9 (isophytol) 500 mg/kg/day (A), or fenofibrate 100mg/kg/day (0). Untreated control (0).) (see Figure 17). 5 Both treatments by oral administration with compound 1 (phytol) or compound 9 (isophytol) reduced the severity of arthritis in the animals. Treatment with fenofibrate had no effect on the severity of arthritis. Example 19 - Treatment of Experimental Allergic Encephalomyelitis (EAE) in 10 vivo At day 0, all rats were treated (immunized) with 200 pL SCH (DA.Ncfl DA spinal cord homogenate, to induce EAE) i.d. at the base of the tail. The rats were then scored according to the following scale for 40 days: 0=Normal 15 1=Tail weakness 2=Tail paralysis 3=Tail paralysis and mild waddle 4=Tail paralysis and severe waddle 5=Tail paralysis and paralysis of one limb 20 6=Tail paralysis and paralysis of a pair of limbs 7=Tetra-paresis 8=Pre-morbid or dead. One group of DA.NcflDA rats (N=6/group) was injected at the base of the tail with 200 pL of compound 1 (phytol) at day 0. 25 EAE began to appear around day 6. The results show a significant difference in severity of inflammatory and paralyzing symptoms of EAE (p < 0.01) between the rats treated with compound 1 (phytol) (*) or untreated control (0), (see Figure 18). 74

Claims

1. Use of a compound comprising one or more isoprenoid units in the manufacture of a medicament for the treatment of an autoimmune condition. 5

2. The use of claim 1, wherein said compound comprises one or more unsaturated isoprenoid units.

3. The use of claim 1, wherein said compound comprises one or more 10 saturated isoprenoid units.

4. The use of claim 2 or 3, wherein at least one of said unsaturated isoprenoid units or saturated isoprenoid units is derivatized with a functional moiety. 15

5. The use of any one of claims 1 to 4, wherein the compound has the following general formula: Sn 'C3 wherein: 20 m + n = an integer from 0-9; ----- represents a single or double bond between C2 and C 3 ; and Y is -OR' or -O-C(=O)R', wherein R' is H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted. 25

6. The use of claim 5, wherein Y is OR'.

7. The use of claim 6, wherein R' is hydrogen.

8. The use of claim 5, wherein Y is -O-C(=O)R'. 30

9. The use of claim 8, wherein R' is C 1 -C 6 alkyl. 75 WO 2007/104790 PCT/EP2007/052457

10. The use of claim 9, wherein R' is CH 3 .

11. The use of claim 5, wherein m + n = an integer from 0-5. 5

12. The use of claim 5, wherein one of m and n is 0, and the other is an integer from 1-5.

13. The use of claim 5, wherein m + n = 3. 10

14. The use of claim 13, wherein one of m and n is 0.

15. The use of claim 14, wherein n is 0. 15

16. The use of claim 5, wherein m + n = 2.

17. The use of claim 5, wherein -- represents a double bond between C 2 and C 3 . 20

18. The use of claim 5, wherein the compound is selected from the group consisting of: (3,7,11,15-Tetramethyl-2-hexadecen- 1-ol); Farnesol (3,7,11-Trimethyl-2,6,10-dodecatrien- 1-ol); Geranylgeraniol (3,7,11,15-Tetramethyl-hexada- 2,6,10,14-tetraen- 1-ol); 25 Farnesyl acetate (Acetic acid 3,7,11-trimethyl-dodeca-2,6,10-trienyl ester); Phytyl acetate (Acetic acid 3,7,11,15-tetra-metyl-hexadec-2-enyl-ester); Di-hydro-phytol (3,7,11,15-Tetramethyl-hexadecan-1-ol); and Di-hydro-phytyl acetate (Acetic acid 3,7,11,15-tetramethyl-hexadecyl ester); 30

19. The use of claim 1, wherein the compound has the general formula: O76R' 76 WO 2007/104790 PCT/EP2007/052457 wherein n+m= an integer from 0 to 9; and R' is H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted.

20. The use of claim 19, wherein m + n = 3. 5

21. The use of claim 20, wherein n is 0.

22. The use of claim 19, wherein R' is hydrogen. 10

23. The use of claim 19, wherein the compound is 3,7,11,15-tetramethyl-1 hexadecen-3-ol.

24. The use of claim 1, wherein the composition has the general formula: iF 1 OR' 15 wherein n+m= an integer from 0 to 9; and R' is H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted.

25. The use of claim 24, wherein m + n = 3. 20

26. The use of claim 25, wherein n is 0.

27. The use of claim 24, wherein R' is C 1 -C 3 alkyl substituted with from 1-3 halogens. 25

28. The use of claim 24, wherein the compound is 6-difluoromethoxy 2,5,7,8-tetramethyl-2-(4,8,12-trimethyl-tridecyl)-chroman.

29. The use of any one of claims 1 to 28, wherein said autoimmune condition is arthritis. 30 77 WO 2007/104790 PCT/EP2007/052457

30. The use of any one of claims 1 to 28, wherein said autoimmune condition is multiple sclerosis.

31. A pharmaceutical composition for use in the treatment of an autoimmune 5 condition, said composition comprising a compound as defined in any one of claims 1 to 28, together with a pharmaceutically acceptable carrier or diluent.

32. A compound as defined in any one of claims 1 to 28, for use in the treatment of an autoimmune condition. 78